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Abstract
Cisplatin (CSP) is a potent and widely used chemotherapeutic agent. However,
clinical efficacy of CSP is compromised due to the elicitation of nephrotoxicity and
ototoxicity. In this study, I have investigated the nephroprotective effects of a
phytochemical – genipin (GP) isolated from gardenia flower (Gardenia jasminoides),
on a murine model of cisplatin-induced nephropathy. CSP-induced renal tissue injury
was characterized by elevated levels of serum blood urea nitrogen (BUN), creatinine
(Cr) and cystatin-C. In addition, levels of kidney injury molecule-1 (KIM-1) were
increased in the renal tissues of CSP administered animals. CSP also induced renal
oxidative stress, evidenced by increased NADPH oxidase, and diminished
superoxide dismutase (SOD) activities. Furthermore, elevated levels of renal 4hydroxynonenal (4-HNE) and 3-nitrotyrosine (3-NY) and diminished glutathione
(GSH) levels signified profound oxidative stress in CSP administered animals. Renal
inflammation was exaggerated in CSP treated animals, which was revealed by
elevated levels of proinflammatory cytokines such as tumor necrosis factor-alpha
(TNF-α) and interleukin-1beta (IL1-β). Increased activation of mitogen activated
protein kinases (MAPKs) was observed in CSP administered animals. Finally, CSP
also induced apoptosis in the renal tissues, revealed by increases in caspase-3/7 and
poly (ADP-ribose) polymerase [PARP] activities, DNA fragmentation, and terminal
deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) staining in the
kidney sections. Interestingly, GP treatment markedly attenuated the cisplatininduced oxidative/nitrative stress, inflammation, and cell death in the kidney, and
improved renal function. Thus, results from this present suggest that GP may
represent

a

promising

new

protective

strategy

against

cisplatin-induced

nephrotoxicity.

Keywords: Cisplatin, genipin, Gardenia jasminoides, nephrotoxicity, oxidative
stress, inflammation, apoptosis, phytochemicals.

viii

)Title and Abstract (in Arabic
تأثير النبات الطبي ,مسحوق الغاردينيا ) (Genipinعلى تسمم الكليتين الناتج عن
السيسبالتين )(Cisplatin

الملخص
انسٍسبالحٍٍ ( )Cisplatinهى عالج كًٍٍبئً لىي وٌسخخذو عهى َطبق واسع .ويع رنك ،حسًى
انكهٍخٍٍ وحسًى األرٍٍَ حعذ يٍ انآلثبس اندبَبٍت اندسًٍت عُذ اسخخذاو هزا انعالج .فً هزِ
انذساست انحبنٍت ،لًُب ببسخكشبف انخصبئص انىلبئٍت عٍ يبٌسًى يسحىق انغبسدٌٍُب
) )genipinوهى يسخخهص َببحً طبً يعضول عٍ صهشة انغشدٌٍُب ( Gardenia
 ،)jasminoidesفً ًَىرج انفئشاٌ انخً حعبًَ يٍ اعخالل انكهٍخٍٍ بعذ يعبندخهب ببنسٍسبالحٍٍ.
ولذ حًٍضث إصببت أَسدت انكهى انُبخى عٍ اسخخذاو انسٍسبالحٍٍ ببسحفبع يسخىٌبث كم يٍ
انٍُخشوخٍٍ وانٍىسٌب فً انذو ( ،)BUNانكشٌبحٍٍٍُ ( )creatinineوانسٍسخبحٍٍ سً
) .(cystatin-Cوببإلضبفت إنى رنك ،حى صٌبدة يسخىٌبث خضيء إصببت انكهى  )KIM-1( 1-فً
أَسدت انكهى .أٌضب بفعم انسٍسبالحٍٍ ،اإلخهبد انخأكسذي انكهىي )ٌ (Oxidative stressخضح
ً ِ َكهٍىحٍذ انٍُكىحٍٍ و األدٍٍَ انًخخضل )،(NADPH oxidase
يٍ صٌبدة يؤكسذ فسفب ِ
ث ثُُبئ ّ
وحمهص َشبط اَضٌى يضبد األكسذة سىبش أكسٍذ دٌسًٍىحبص (( Superoxide dismutase
.)(SOD
وعالوة عهى رنك ،نىحع يسخىٌبث يشحفعت يٍ ) (Renal 4-hydroxynonenal (4-HNEو
) (3-nitrotyrosine (3-NYو حمهص يسخىٌبث اندهىحبثٍىٌ ( )GSHيًب ٌذل عهى حذود
أكسذة عًٍمت فً انحٍىاَبث انًعبندت ببنسٍسبالحٍٍ .ببإلضبفت انى رنك فمذ حى انكشف عٍ
يسخىٌبث يٍ االنخهبة انكهىي انًىخىد فً أَسدت انفئشاٌ عٍ طشٌك وخىد يسخىٌبث يشحفعت
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يٍ انسٍخىكٍُبث انًحفضة نالنخهبة يثم عبيم َخش انىسو أنفب ( )TNF-αواَخشنٍىكٍٍ ).(IL-1β
ولذ نىحع صٌبدة حفعٍم وَشبط ) . (MAPKsوأخٍشا يىث انخالٌب انًبشيح  ،بفعم انسٍسبالحٍٍ
فً أَسدت انكهى ،انخً كشفج عُهب صٌبداث فً اَضًٌبث انكبسببص  Caspases 3/7و poly
) (ADP-ribose) polymerase (PARPوحفخٍج انحًض انُىوي ،وأٌضب عٍ طشٌك حهىٌٍ
وحصبغ خالٌب انكهى انًخخهفت ببسخخذاو .TUNEL staining
ويٍ انًثٍش نالهخًبو ،أٌ انعالج ببسخخذاو هزا انًسخخهص انُببحً انطبً ،يسحىق انغبسدٌٍُب
)ٌ ،(Genipinؤدي بشكم يهحىظ انى حمهٍم انخأكسذ انُبحح عٍ انسٍسبالحٍٍ ،واالنخهبببث،
ويىث انخالٌب انًبشيح فً انكهى ،وححسٍٍ وظبئف انكهى .وهكزاَ ،دذ أٌ انُخبئح حشً إنى أٌ
هزا انًسخخهص ) (Genipinلذ ًٌثم اسخشاحٍدٍت ولبئٍت خذٌذة واعذة ضذ االعخالل انكهىي
انُبخى عٍ انسٍسبالحٍٍ.
مفاهيم البحث الرئيسية :سٍسبالحٍٍ .يسحىق انغبسدٌٍُب .غبسدٌٍُب ٌبسًٍٍُت .حسًى انكهٍخٍٍ،
األكسذة  ،االنخهبة  ،يىث انخالٌب انًبشيح .انٍُبحبث انطبٍت.
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Chapter 1 : Introduction
1.1 Cisplatin (CP) Discovery and Clinical Applications

Cisplatin (CP) is a chemotherapeutic agent. International union of pure and
applied chemistry (IUPAC) nomenclature refers CP as cis-diamminedichloroplatinum
II. Chemically, CP was the first molecule in the class of platinum-containing anticancer drugs synthesized. Subsequently, carboplatin and oxaliplatin have been
developed. CP was first synthesized by Michel Peyrone in 1845 (Burchenal, Kalaher,
Dew, & Lokys, 1979; Galluzzi et al., 2014). Then, American chemist Barnett
Rosenberg characterized the anti-proliferative effects of cisplatin, first in Escherichia
coli, and then in solid and hematopoietic tumor xenografts (Galluzzi, et al., 2014;
Rosenberg, Vancamp, & Krigas, 1965). In fact, Rosenberg’s findings laid the
foundation for unraveling the molecular mechanisms governing CP anti-cancer
effects, clinical efficacy, safety and adverse effects (L. Kelland, 2007; L. R. Kelland
et al., 1999; Lebwohl & Canetta, 1998).

Figure 1.1: Cisplatin Structure

However, in 1978 it was approved by United States food and drug
administration (USFDA) for clinical use to treat testicular and bladder cancers (L.
Kelland, 2007). Since then, cisplatin has been licensed worldwide for the treatment of
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several solid tumors originating from head and neck, lung, colorectal, cervical,
ovarian and bladder (Galanski, 2006; Lebwohl & Canetta, 1998; Prestayko, D'Aoust,
Issell, & Crooke, 1979).
CP has been found to be highly efficient for treating testicular germ cell
cancers (Feldman, Bosl, Sheinfeld, & Motzer, 2008; Winter & Albers, 2011).
However, significant number of patients with lung, prostate and colorectal cancer
patients tend to develop resistance to CP therapy (Galluzzi, et al., 2014 present and
future; Koberle, Tomicic, Usanova, & Kaina, 2010). Despite being a well-known and
powerful anti-proliferative drug, CP usage is accompanied with moderate-to-severe
nephrotoxicity, ototoxicity and neurotoxicity (Galluzzi, et al., 2014).
Therefore, efforts have been made towards the development of novel
derivatives of CP that would elicit robust therapeutic responses along with minimized
side effects (Galluzzi, et al., 2014). Thus, it led to the development of additional
platinum derivatives in clinical practice such as carboplatin and oxaliplatin (Mandala,
Ferretti, & Barni, 2004; Tattersall, 2002). FDA has approved carboplatin in 1989 for
the treatment of ovarian cancer and oxaliplatin in the 5-fluorouracil (5-FU) and
folinic acid-containing cocktail regimen for treating colorectal cancer (Mandala, et
al., 2004; Tattersall, 2002). Carboplatin antineoplastic actions are similar to cisplatin,
reflecting the fact that the active forms of these drugs are identical. However,
carboplatin appears to be less nephron and neurotoxic than cisplatin, and this perhaps
reflects its reduced biological potency (Harrap, 1985).
However, significant proportion of CP-resistant tumors are resistant not only
to carboplatin but also to oxaliplatin as well as to other chemotherapeutic agents
(Gore et al., 1989; Hamaguchi et al., 1993; Negoro et al., 2009). These findings had
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led to the development of additional platinum derivatives such as picoplatin and
satraplatin. However, phase II clinical trials revealed that neither picoplatin nor
satraplatin provide consistent advantages over CP, oxaliplatin or carboplatin-based
chemotherapy (Choy, 2006; Eckardt et al., 2009; Monneret, 2011; Sternberg et al.,
2009).
1.2 Disadvantages of CP Chemotherapy
Clinical studies have revealed that approximately 30-50% of patients treated
with CP could develop hearing loss and 14% - 57% affected by neurotoxicity.
Furthermore, 70% of patients treated with CP could be affected by nephrotoxicity
(Rathinam, Ghosh, Neumann, & Jamesdaniel, 2015 renal, and neuronal cells is
associated with nitration and downregulation of LMO4; Rubin et al., 1995; Skinner et
al., 1998; Travis et al., 2014). In spite of these disadvantages, CP continues to remain
as standard chemotherapy regimen for treatment of cancers arising from head and
neck, testicular, cervical, ovaries and bladder. This could be attributed to the findings
that other platinum based drugs failed to provide firm clinical efficacy (Coppin et al.,
1996; Loehrer, Gonin, Nichols, Weathers, & Einhorn, 1998; Planting et al., 1999;
Rose et al., 1999).
Nephrotoxicity is the most serious dose-limiting side effect of CP therapy
(Sastry & Kellie, 2005). CP-induced nephrotoxicity can manifest with various types
of symptoms such as acute kidney injury (AKI), hypomagnesemia, Fanconi-like
syndrome, distal renal tubular acidosis, hypocalcemia, renal salt wasting, renal
concentrating defect, hyperuricemia, transient proteinuria and erythropoietin
deficiency (Miller, Tadagavadi, Ramesh, & Reeves, 2010). However, the most
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serious and life-threating side effect is AKI, which occurs in 20-30% of patients
treated with CP (G. S. Oh et al., 2014).

1.2.1 Risk Factors for CP-Induced Nephrotoxicity
Several risk factors have been identified that could pre-dispose the patients to
develop CP-induced nephrotoxicity. These include, high cumulative doses, increased
frequency of treatment, geriatric population, smoking and hypoalbuminemia. While
organic cation transporter-2 (OCT2) polymorphisms have been associated with
decreased risk for the development of CP-induced nephrotoxicity (Miller, et al.,
2010).

1.2.2 Biomarkers for Detecting CP-Induced Nephrotoxicity
Since the kidneys are the major organ affected with CP treatment, it is
important to diagnose and treat nephrotoxicity at the earliest to avoid the morbidity
and mortality associated with AKI. Therefore, robust and validated biomarkers are
vital to aid for prompt diagnosis and management of CP-induced AKI. The most
commonly used biomarkers till date are serum creatinine (Cr) and blood urea nitrogen
(BUN). Moreover, several enzymes secreted in urine such as N-acetyl-β-dglucosaminidase

(NAG),

lactate

dehydrogenase

(LDH)

and

aspartate

aminotransferase (AST), have been suggested as nephrotoxic biomarkers in different
studies (Tonomura, Tsuchiya, Torii, & Uehara, 2010). Unfortunately, the
conventional biomarkers such as Cr and BUN are characterized by low detection
sensitivity. Therefore, there is an urgent need for development of biomarkers with
higher sensitivity to ensure that CP-elicited nephrotoxicity is being diagnosed with
higher precision. USFDA and the European Medicines Agency (EMEA) recently
published guidelines stating that several other urinary nephrotoxic biomarkers
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including total protein, albumin, kidney injury molecule-1 (KIM-1), clusterin (CLU),
β2-microglobulin (B2M), cystatin-c (CysC), and trefoil factor 3, has been shown in
the regulatory decision-making during the management of CP-induced nephrotoxicity
(Tonomura, et al., 2010).
Furthermore, neutrophil gelatinase-associated lipocalin (NGAL) has been
recently recognized as a novel candidate for detecting drug-induced nephrotoxicity
(Haase, Bellomo, Devarajan, Schlattmann, & Haase-Fielitz, 2009). However, KIM-1
with greater accuracy and sensitivity and shows the rapid increase in urine in a timedependent manner. Regarding the early elevation of KIM-1, it is known that KIM-1
mRNA is rapidly expressed and translated to protein early after the injury of renal
tubule (Bonventre, 2009; Tonomura, et al., 2010). KIM-1 is a type I cell membrane
glycoprotein, which is involved in the regulation of the innate and adaptive immune
responses. Since, the major target site of CP toxicity is the S3 segment of the
proximal tubule, urinary KIM-1 can be considered as a specific biomarker of
proximal tubular injury. (Bonventre, 2009; Prozialeck et al., 2009).
In contrast, cystatin C (CysC) is known as functional biomarker because it can
freely pass through glomerular capillary wall due to its low-molecular weight and is
almost completely reabsorbed by epithelial cells in proximal tubules. Therefore,
CysC serum concentration correlates closely to the glomerular filtration rate (GFR).
CysC is a secreted, extracellular cystatin protease inhibitor that belongs to the
cystatin superfamily. Its measurement in serum and /or plasma has been proposed as
an indicator of drug-induced nephrotoxicity that is less affected by factors such as
gender, age, muscle mass, and preexisting liver diseases (Herget-Rosenthal, van
Wijk, Brocker-Preuss, & Bokenkamp, 2007; Tonomura, et al., 2010).

6

1.3 Why Kidneys are Prime Target for CP Toxicity?
1.3.1 Transporter-mediated Mechanism for CP Accumulation in Kidneys
Cisplatin enters renal tubular cells by passive diffusion or transportermediated facilitated diffusion (Peres & da Cunha, 2013). Two different membrane
transporters have been identified that are capable of transporting CP in to the cells,
chiefly Ctr1 (copper transporter) and OCT2. Ctr1 transporter is highly expressed in
adult kidney cells and it localizes to the basolateral membrane of the proximal
convoluted tubule (Pabla, Murphy, Liu, & Dong, 2009). Downregulation of Ctr1
transporter expression decreases both CP uptake and cytotoxicity effects, suggesting
that Ctr1 transporter could be considered as an important uptake mechanism of CP in
cells (Pabla, et al., 2009). OCT2 also plays an important role in transporting CP into
cells especially in the proximal tubules of kidneys. Three isoforms of OCT were
identified in human subjects. OCT2 is mainly expressed in renal tissues, while OCT1
in liver, and OCT3 in placenta. Downregulation of OCT2 accounts for lowering the
risk of CP uptake, accumulation and development of nephrotoxicity (Miller, et al.,
2010). Interestingly, CP does not interact with OCT1, which could emphasize the
drug's organ and cell-specific toxicity (Peres & da Cunha, 2013).

1.3.2 Metabolic Conversion of CP to Nephrotoxins and Accumulation in
Kidneys
Upon entry into the cells, CP undergoes metabolic activation in the kidneys to
become a more potent toxin. Formation of glutathione conjugates is the first step in
this process, mediated by glutathione-S-transferase. Once glutathione conjugates pass
through the kidneys, they are cleaved by gamma glutamyl transpeptidase (GGT)
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expressed on the surface of proximal tubule cells into cysteinyl-glycine-conjugates.
These are further metabolized to cysteine conjugates by enzymes expressed on the
surface of the proximal tubule cells called aminodipeptidases. Cysteine conjugates
are finally transported to proximal tubule cells where it is further metabolized to
highly reactive thiols (Townsend, Deng, Zhang, Lapus, & Hanigan, 2003). These
highly reactive thiols interact with macromolecules, affect their structure, function,
and eventually leading to renal cell death. It is pertinent to note that mice deficient in
GGT were resistant to the nephrotoxic effects of CP (Peres & da Cunha, 2013).
1.4 Clinical Pharmacology of CP and its Mechanism of Anti - Cancer
Activity
Upon systemic infusion, unbound CP has been estimated to have final plasma
elimination half-life of 30-45 minutes, with renal elimination accounting for more
than 25% of the total elimination. CP is administered either intravenously or shortterm infusion in physiological saline or intraperitoneally, binds to serum protein by
about 90%, distributes to most tissues and is cleared by the kidney in unchanged form
(Royer et al., 2005) (Murry, 1997). In the aqueous environment, chloride atoms of CP
are replaced by water molecules, and this result in the formation of positively charged
electrophile. The electrophile reacts with nucleophilic sites of the DNA, RNA and
protein to form different adducts. This interaction between cisplatin and DNA, results
in the formation of either interstrand or intrastrand crosslinks (Figure 1.2), thereby
arresting DNA synthesis and replication in rapidly proliferating cancer cells (D.
Wang & Lippard, 2005).
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Figure 1.2: Mechanism of CP action

1.5 Biochemical and Molecular Mechanisms Purported for CP-Induced
Nephrotoxicity
1.5.1 DNA Damage and Mitochondrial Dysfunction
Platinum compounds mediate their cytotoxic effect through their interaction
with the DNA. A positively charged metabolite of CP is mostly accumulated within
the negatively charged mitochondria. This could explain the sensitivity of the renal
proximal tubule to CP, as this particular segment possesses the highest mitochondrial
density in kidneys (Miller, et al., 2010; Townsend, et al., 2003). Due to poor DNA
repair machinery, mitochondrial DNA is more prone for CP damage rather than
nuclear DNA (Figure 1.3) (Olivero, Chang, Lopez-Larraza, Semino-Mora, & Poirier,
1997).
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Figure 1.3: CP-induced DNA damage and cell death

Energy production in the mitochondria are also disrupted by CP. Fatty acids
serve as the major source of energy in the proximal tubule cells and are the primary
target of CP-induced kidney injury. CP causes fatty acid oxidation inhibition in
proximal tubule cells through interfering with PPAR-α mediated expression of genes
involved in cellular fatty acid utilization (Li et al., 2004). In addition, CP also inhibits
mitochondrial respiration. As a result of this, intracellular ATP generation is
decreased, that causes further disruption in the mitochondrial energy metabolism
through cascade of biochemical changes culminating in the apoptotic cell death of
renal parenchyma (Kruidering, Van de Water, de Heer, Mulder, & Nagelkerke,
1997). Specifically, mitochondrial dysfunction occurs following CP treatment is due
to the decline in membrane electrochemical potential, marked decrease in
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mitochondrial calcium uptake and depletion of mitochondrial antioxidant defense
mechanisms (Kruidering, et al., 1997). In fact, a recent study demonstrated that
rodents treated with mitochondria targeted antioxidants protected against CP-induced
nephrotoxicity without compromising its anti-cancer activity (Partha Mukhopadhyay
et al., 2012).

1.5.2 Cell Transport System Alterations
CP interferes with transporter of water and renal tubular cell nutrients that is
mediated by Na+ pumps in the apical and basolateral face of the renal proximal
tubular cells, such as Na+/K+/ATPase, Na-K-2Cl cotransporter, and type III Na+/H+
exchanger, and water-permeable channels such as aquaporin 1, 2, and 3. CP also
inhibits the activity of transporters in the brush border. CP-induced renal injury may
compromise the integrity of the cytoskeleton and cell polarity, thus interfering with
H+, K+, Mg2+, and Ca2+ ions homeostasis and contributing to lower ion reabsorption
rates in the proximal and distal tubules and increased excretion of these ions in urine.
Additionally, loss of the tubular epithelial cell barrier and/or junctions between cells
in CP-induced tubular injury could also force the glomerular filtrate to flow back into
blood circulation, producing significant decrease in glomerular filtration rate (GRF)
(Lajer et al., 2005; Peres & da Cunha, 2013).

1.5.3 Oxidative Stress
Oxidative stress is involved in CP-induced nephrotoxicity. Several
mechanisms have been proposed that are associated with renal injury, which include,
reactive oxygen species (ROS) generation, depletion of antioxidant systems, and
stimulation of renal accumulation of lipid peroxidation products (Peres & da Cunha,
2013). These mechanisms lead to the activation of oxidative metabolism secondary to
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the stimulation of ROS production, including superoxide anions (O2), hydrogen
peroxide (H2O2), and hydroxyl radicals (OH). Furthermore, CP also depletes the
antioxidant defense mechanisms such as glutathione (GSH), superoxide dismutase
(SOD), catalase (CAT), and glutathione peroxidase (GPx). In addition, nitrative stress
is also involved in the renal damage through production of high levels of nitric oxide
(NO), possibly as a result of induced synthesis of nitric oxide synthase (iNOS),
leading to the continuous formation of peroxynitrite (ONOO-), which contribute to
CP-induced renal damage by reacting with O2. Therefore, both reactive oxygen and
nitrogen species generation following CP treatment leads to significant damage to
cell structure and function, including lipid peroxidation, protein nitration, enzyme
inactivation, and DNA breaks. Eventually, this phenomenon leads to cellular
dysfunction and signaling for the activation of pro-apoptotic pathways, causing cell
death and kidney damage (Cetin et al., 2006; Peres & da Cunha, 2013) (Pál Pacher,
Joseph S. Beckman, & Lucas Liaudet, 2007).

1.5.4 Inflammatory Response
In addition to direct toxicity that exists following CP administration,
inflammation plays a pivotal role in renal injury due to several inflammatory
mediators. Different chemokines and cytokines are produced and released to the site
of renal tissue injury. CP activates phosphorylation and subsequent translocation of
nuclear factor kappa -B (NFκB) transcription factor to the nucleus that consequently
promotes the transcription of specific genes encoding inflammatory mediators and
causing immune, proliferative, anti-apoptotic, and inflammatory responses (Miller, et
al., 2010). This event leads to increased expression of tumor necrosis factor alpha
(TNF-α) in kidney tubular cells. TNF-α is the prototypical inflammatory cytokine that
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plays an important role in the host-defense mechanisms against infectious diseases
and other chronic inflammatory diseases. Several studies have addressed the role of
TNF-α in the pathogenesis of CP-induced acute renal failure. In fact, treatment of
animals with specific TNF-α inhibitors or genetic ablation of TNF-α conferred
marked renal protection against CP-induced nephrotoxicity (Ramesh & Reeves,
2002). These observations revealed the important contribution of TNF-α in the
pathogenesis

of

CP-induced

renal

toxicity.

Furthermore,

several

studies

independently have confirmed the above findings (Y. K. Kim et al., 2003; Tsuruya et
al., 2003).
TNF-α can stimulate renal injury and tubular cell death directly via TNF
receptor type 1 (TNFR1) and indirectly by evoking strong inflammatory response
through TNF receptor type 2 (TNFR2). Moreover, TNF-α/TNFR2 signaling
contributes to CP nephrotoxicity and may enhance the pro-apoptotic effects arising
from the activation of TNFR1. Additionally, TNF-α is responsible for the activation
of a large network of proinflammatory cytokines such as interleukins IL-1β, IL-4, IL6, transforming growth factor-β1 (TGF-β 1) and monocyte chemotactic protein-1
(MCP-1). Furthermore, TNF-α induces the expression of adhesion molecules, such as
intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1
(VCAM-1), resulting in the invasion of inflammatory cells in to the renal parenchyma
(Peres & da Cunha, 2013).
Mitogen-activated protein kinases (MAPK) are protein kinases that are
involved in directing cellular responses to a diverse range of stimuli, such as
mitogens, osmotic stress, heat shock and proinflammatory cytokines. Moreover,
MAPK’s

regulate

cell

functions

including

proliferation,

gene

expression,
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differentiation, mitosis, cell survival, and apoptosis. Different stimulus such as
physical, biological or chemical, causes initiation of cellular stress, inflammatory
response and apoptotic pathways that eventually induced the production of c-Jun Nterminal kinases (JNKs) and p38 MAPK kinases. In addition, a cascade of
extracellular-signal-regulated kinases (ERKs) is induced mostly by cell death and cell
survival growth factors. Therefore, different activation patterns of these three main
MAPK pathways (ERK, JNK, and p38) have been involved in the pathogenesis of
CP-induced nephrotoxicity (dos Santos, Carvalho Rodrigues, Martins, & dos Santos,
2012; Pabla & Dong, 2008). p38 MAPK activation leads to the synthesis of TNF-α in
CP-induced renal inflammation. It has been demonstrated that the activation of
MAPK p38 in neutrophils causes Iκβ (an inhibitor of NF-κβ) degradation,
consequently promoting the activation and migration of NF-κB to the nucleus, which
culminates in the generation of pro-inflammatory cytokines including TNF-α.
Consequently, TNF-α and some other inflammatory mediators, form a loop feedback
which induces the transcription of genes of inflammatory mediators (Peres & da
Cunha, 2013; G. Ramesh & W. B. Reeves, 2005).

1.5.5 Apoptosis Pathways Activation
Nephrotoxic dose of CP has been shown to initiate several apoptotic pathways
in renal epithelial cell death via extrinsic and intrinsic pathways (Shiraishi et al.,
2000). CP recruits extrinsic pathway by activating death receptors such as TNF
receptors located in the basolateral membrane and their main ligands including Fas
and TNF-α, and the activation of these receptors increases the activity of caspase 8
and eventually resulting in the apoptosis. Intrinsic pathway or mitochondrial and
endoplasmic reticulum stress pathway enhances the pro-apoptotic proteins Bax and
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Bak to undergo structural modifications and alter the integrity of the mitochondrial
membrane to cause the release of apoptogenic factors such as cytochrome C
(caspases activator) and apoptosis-inducing factor (AIF), a caspase-independent cell
death promoter (Peres & da Cunha, 2013). Both pathways induces the activation of
specific proteases called executioner caspases (caspase-3 and caspase-7), resulting in
the characteristic morphological changes such as membrane degradation, cell
shrinkage, and DNA fragmentation, which are reminiscent of apoptosis (Pabla &
Dong, 2008; Peres & da Cunha, 2013; Sancho-Martinez, Prieto-Garcia, Prieto,
Lopez-Novoa, & Lopez-Hernandez, 2012).
Caspases are a family of cell death proteases that plays an important role in
the execution phase of apoptosis in the renal tubular epithelial cell death both in vivo
and in vitro (Jiang, Wang, Huang, Yang, & Dong, 2009). Activation of caspases
occurs after CP treatment of renal epithelial cells and inhibition of caspase activity
suppress its role in cell death induction. P53 is a tumor suppressor gene that causes
cell cycle arrest or apoptosis in response to DNA damage, hypoxia and oncogene
activation (Bassett, Wang, Rastinejad, & El-Deiry, 2008). CP administration has been
reported to activate the p53 transcription. However, pharmacological inhibition of
p53 transcriptional activity or genetic ablation/repression reduces CP-induced caspase
activation, apoptosis, ameliorated CP-induced renal apoptosis, and renal tissue injury
(Wei et al., 2007). In sum, CP-induced cell injury and cell death involves number of
pathways including oxidative stress, pro-inflammatory cytokines generation, and
activation of intrinsic and extrinsic apoptotic pathways.
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1.6 Strategies for Ameliorating CP - Induced Nephrotoxicity
Vigorous hydration with saline and simultaneous administration of mannitol
before, during and after cisplatin administration have been shown to reduce the risk
for CP-induced nephrotoxicity (Ali & Al Moundhri, 2006; G. S. Oh, et al., 2014).
Amifostine (an organic thiophosphate) also reduces CP-induced nephrotoxicity.
Amifostine mechanism of renoprotection is purported through the scavenging of
oxygen free radicals, via generation of GSH (Ali & Al Moundhri, 2006; Asna et al.,
2005). In addition, erythropoietin has been shown to confer protection against CPinduced nephrotoxicity (Yalcin et al., 2003). In addition to its essential role as
hematopoietic agent, erythropoietin inhibits apoptotic cell death, enhances tubular
epithelial regeneration and promotes renal functional recovery in hypoxic or ischemic
acute renal injury (Yalcin, et al., 2003).
Salicylates are anti-inflammatory agents used in the treatment of various
inflammatory ailments. Salicylates confer anti-inflammatory activity by inhibiting
cyclooxygenase activity and prostaglandin synthesis. Furthermore, high doses of
salicylates are able to stabilize the inhibitor of kappa-B (IκB) enzyme as well as
reduce NFκB transcriptional activity, that consequently attenuates TNF-α generation
and reduces renal inflammatory response during the CP-induced nephrotoxicity(G. S.
Oh, et al., 2014). (Ramesh & Reeves, 2004). However, these approaches have met
with limited clinical success, since CP-induced nephrotoxicity could not be
abrogated. Therefore, there is an urgent need to develop agents that can confer
renoprotection, without compromising the anti-cancer activity of CSP.
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1.6.1 Phytochemicals as Cytoprotective Agents for Mitigating CP – Induced
Nephrotoxicity
Phytochemicals are bioactive non-nutrient plant compounds that are widely
distributed in plant kingdom. Regular consumption of fruits and vegetables were
associated with reduced risk for the development of major chronic diseases such as
metabolic syndrome, cardiovascular and inflammatory diseases. Presently, more than
5000 phytochemicals were identified. Despite this development, their pharmacology
and health benefits are hitherto unknown (R. H. Liu, 2003). In fact, USFDA approved
anti-cancer drug paclitaxel and anti-malarial drug artemisinin are phytochemicals
derived from Taxus brevifolia and Artimesia annua (Morejohn & Fosket, 1991) (Tu,
2016). In addition, anti-diabetic drug belonging to the chemical class biguanide was
originally isolated from Galega officinalis (Witters, 2001). These developments
provide indication that phytochemicals have tremendous translational potential for
the treatment of various diseases. In this direction, several phytochemicals were
evaluated for cytoprotective effects against CP-induced nephrotoxicity (Ojha et al.,
2016).
In the present study, we have investigated the nephroprotective actions of
genipin (GP) in a murine model of CP-induced nephrotoxicity. GP is a phytochemical
extracted from the fruit of Gardenia jasminoides (Figure 1.4). This plant belongs to
the coffee family and it is native to the subtropical countries of Africa, Asia and
Pacific islands (Manickam, Sreedharan, & Elumalai, 2014). In traditional Chinese
medical practice, GP formulations is used for the treatment of inflammation
associated pain, hypertension, hepatic disorders (Ko & Moon, 2015). Recently, GP
chemo-preventive effects were also recognized (Ko & Moon, 2015).
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Structure of Genipin

Gardenia jasminoides

Figure 1.4: Structure of genipin and its natural source

1.7 Aims and Objectives of the Study
GP is a terpinoid molecule and it is widely used in the pharmaceutical
industry as a cross-linking agent in the synthesis of various biopolymers, and used as
drug delivery agents. Because of natural availability and low cytotoxicity, GP is
pursued for the development of novel cross-linking agents. In addition, GP also
serves as backbone for the synthesis of various alkaloids during medicinal chemistry
research (Tsai, Tseng, Chen, & Tsai, 2002). Previous studies have indicated that GP
possesses anti-inflammatory and anti-oxidant properties (Koriyama et al., 2010).
Furthermore, GP has been shown to ameliorate hepatic ischemia reperfusion injury,
steatosis, autoimmune hepatitis and fibrosis in rodents (J. Kim, Kim, & Lee, 2013)
(Ma et al., 2012) (S.-J. Kim, Kim, Lee, Kwak, & Lee, 2010) (Inao et al., 2004).
Similarly, GP has been reported to attenuate myocardial tissue injury (Paul et al.,
2012) and suppresses neuro-inflammation (Koo et al., 2004). In addition, GP
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inhibited hyperglycemia-induced renal tissue injury by diminishing oxidative stress
and inflammation (Qiu et al., 2012).
However, there are no reports available on GP nephroprotective activity
against CP-induced renal toxicity. Hence, we have undertaken this study to determine
and investigate the GP nephroprotective actions, in murine model of CP-induced
nephrotoxicity. Specific objectives of this project are outlined below.
1. Investigate the GP nephroprotective effect against CP-induced nephrotoxicity
in mice.
2. Investigate the pre-treatment (prophylaxis) and post-treatment (therapeutic)
effects of GP against CP-induced nephrotoxicity.
3. Investigate the biochemical mechanisms governing GP nephroprotective
actions.
4. In specific, the role of oxidative stress, inflammation and cell death pathways
in ameliorating CP-induced nephrotoxicy will be determined.
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Chapter 2 : Materials and Methods
2.1 Animals and Drug Treatment
All animals experimentation protocols adhered to the National Institutes of
Health (Bethesda, MD, USA) guidelines for responsible use of laboratory animals
and were approved by institutional animal care and use committee of the United Arab
Emirates University. C57BL/6J (6-8 week-old male mice) were purchased from the
Jackson laboratory (Bar Harbor, ME, USA). Animals were maintained in
temperature-controlled facility, with 12-hr light/dark cycle and provided access to
water and food ad libitum. Genipin (GP) was obtained from Santa Cruz
biotechnology (Dallas, TX, USA). Cisplatin (CP) was purchased from Sigma
chemicals (St Louis, MO, USA). GP (1 – 10 mg/kg) was administered via
intraperitoneal injections (I.P) either 2hrs before or 12hrs after CP administration.
Animals were sacrificed 72hrs after single dose of CP (20 mg/kg; I.P). Animals were
anesthetized with tribromomethanol (0.2 ml/10 gm body weight). Blood samples
were collected by retro-orbital puncture and later euthanized by cervical dislocation.
After ensuring the death of animals, they were dissected and kidneys were removed
and snap frozen in liquid nitrogen for biochemical investigations or placed in 10%
neutral buffered formalin (Electron microscopy sciences, Hatfield, PA, USA) for
histological evaluations. Unless specified, all fine reagents were obtained from Sigma
chemicals.
2.2 Determination of Renal Function
Serum levels of blood urea nitrogen (BUN) and creatinine (Cr) was
determiend using IDEXX VetTest chemistry analyzer (IDEXX Lab, Hoofddorp, The
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Netherlands). Test kits were procured from IDEXX lab and samples were analyzed
per the protocol supplied by the manufacturer (Partha Mukhopadhyay et al., 2010).
2.3 Determination of Serum Cystatin C
Levels of cystatin c in serum samples were determined using commercially
available ELISA kit (R & D systems, MN, USA). Samples were subjected to ELISA
assay as per the protocol supplied with the kit. In brief, 50 L of assay diluent was
added to the 96-well microtiter plate, followed by 50 L of serum samples or
standards, and incubated for 2 hours at room temperature (RT). After washing, 100
L of cystatin c conjugate solution was added and incubated at RT for 2 hours.
Subsequent to washing, wells were probed with 100 L substrate solution and
absorbance was determined at 450 nm using microtiter plate reader [Molecular
Devices, Sunnyvale, CA, USA]. Values are expressed as ng/ml.
2.4 Determination of Kidney Injury Molecule -1 (KIM-1) in Renal Tissues
Renal tissues were homogenized with tissue lysis buffer (Thermo Fischer
Scientific, Paisley, UK). Protein content in the homogenates was determined with
Lowry reagent (Bio Rad, CA, USA). Levels of KIM-1 in the renal tissues were
determined with the commercially available kit (R & D systems, MN, USA) and the
protocol was identical to that of cystatin C measurement. Values were expressed as
pg/mg protein.
2.5 Histological Evaluation of CP-Induced Renal Injury
After fixation of the renal tissues in 10 % neutral buffered formalin for 72
hours, samples were processed as follows:

1. 70 % ethanol for 1 hour
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2. 95 % ethanol for 1 hour
3. Absolute ethanol for 1 hour X 3 changes
4. Xylene 1 hour X 2 changes
5. First wax (Paraplast X-tra; Thermo Fischer Scientific, Paisley, UK) at
58°C for 1 hour
6. Second wax (Paraplast X-tra) at 58°C 1 hour
7. Processed samples were embedded in tissue cassettes and allowed to cool
down to RT.
8. 5 m paraffin sections were obtained using microtome (Thermo Fischer
Scientific, Paisley, UK). Sections are air dried and placed at hot plate at 58°C
for 2 hours. The sections were stored in slide boxes, until staining.

2.5.1 Periodic acid-Schiff Staining (PAS) of Paraffin Sections
Slides were placed in a rack, and deparaffinization was performed using glass
chamber as per the protocol provided below:
Solution
Xylene
Xylene
Xylene : Ethanol (1:1)
100% Ethanol
100% Ethanol
95% Ethanol
70% Ethanol
50% Ethanol

Incubation time
3 min
3 min
3 min
3 min
3 min
3 min
3 min
3 min

After deparaffinization, slides are placed in distilled water, until further processing of
the sections. PAS staining of the renal sections was performed using the kit purchased
from American Master Tech (Lodi, CA, USA). The sections were immersed in 0.5 %
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periodic acid and incubated for 7 min and washed in running tap water for 1 min.
Next, sections were covered with Schiff solution and incubated for 15 min, followed
by washing in running tap water for 5 min. Sections were counterstained with
Mayer’s hematoxylin for 2 min and washed in running water for 1 min. Finally,
sections were dehydrated in absolute alcohol for 1 min, and xylene, and permanently
mounted with cover slips. Slides were air-dried and observed using light microscope
(Carl Zeiss, Germany). Tubular necrosis was characterized by the loss of proximal
tubular brush border, blebbing of apical membranes, epithelial detachment from
basement membrane or intraluminal hyaline cast formation (Partha Mukhopadhyay,
et al., 2010).
2.6 Determination of NADPH oxidase Activity in Renal Tissues
Renal tissues were washed in ice-cold phosphate buffered saline (PBS),
homogenized in buffer containing 20 mM KH2PO4 (pH 7.0), protease and
phosphatase inhibitors cocktail tablet (Calbiochem) NADPH oxidase activity of the
renal homogenates was measured using the method described earlier (Abid, Spokes,
Shih, & Aird, 2007). In brief, photon emission from the chromogenic substrate
lucigenin as a function of acceptance of electron/O2 generated by the NADPH
oxidase complex was measured every 15 seconds for 10 min in a luminometer
(Molecular Devices). The composition of NADPH oxidase assay buffer is: 250 mM
HEPES (pH 7.4), 120 mM NaCl, 5.9 mM KCl, 1.2 mM MgSO4, 1.75 mM CaCl2,
11mM glucose, 0.5 mM EDTA, 100 M NADH and 5 M lucigenin. The data were
converted to relative light units/min/mg of protein and expressed as % activity.
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2.7 Determination of Superoxide dismutase (SOD) Activity in Renal Tissues
SOD activities in renal tissues were determined using the assay kit obtained
from Trevigen, Inc. (Gaithersburg, MD, USA). Protocol for determining the enzyme
activity was supplied with kit. In this assay, O2 generated from the conversion of
xanthine to uric acid and H2O2 by xanthine oxidase (XOD), reduced WST-1
(colorless) to WST-1 formazan (chromogen), which absorbs light at 450 nm. SOD
present in the samples would reduce the O2

concentration and inhibits the

generation of WST-1 formazan (chromogen). Therefore, the extent of reduction in the
production of WST-1 formazan is proportional to the SOD activity in the tissues. For
instance, higher SOD activity in the samples will result in diminished formation of
WST-1 formazan. Values were expressed as units/mg protein.
2.8 Determination of GSH content in Renal Tissues
GSH levels in the tissues were determined using the kit obtained from
Trevigen, Inc. (Gaithersburg, MD, USA). This kit uses the enzymatic recycling
method for the quantification of GSH. GSH reductase reduces the oxidized
glutathione (GSSG) to reduced GSG. As shown in Figure 2.1, the sulfhydryl group of
GSH reacts with 5,5’ dithiobis-2-nitrobenzoic acid (DTNB) to generate yellow
chromogen -5-thio-2-nitrobenzoic acid (TNB), which absorbs at 405 nm. The rate of
TNB production is directly proportional to the concentration of GSH in tissues. GSH
content was expressed as mol / mg protein.

24

Figure 2.1: GSH assay principle

2.9 Determination of 4-hydroxynonenal (4-HNE) in Renal Tissues
Lipid peroxides are unstable indicators of oxidative stress in cells that
decompose to form more complex and reactive compounds like malondialdehyde and
4-HNE. Determining the end products of lipid peroxidation is one of the most widely
accepted assays for oxidative damage. 4-HNE in the renal tissues were determined
using ELISA kit procured from Cell Biolabs, Inc (San Diego, CA, USA). The assay
was accomplished by following the protocol supplied with the kit. First, an HNE
conjugate was coated on an ELISA plate. The unknown HNE protein samples or
HNE standards are then added to the HNE conjugate reabsorbed ELISA plate. After
incubation for 1 hour at RT, an anti-4HNE polyclonal antibody was added, followed
by an HRP conjugated secondary antibody, and incubated for 1 hour at RT. After
washing of wells, substrate solution was added and absorbance was measured at 450
nm. 4-HNE content in the samples was expressed as nmol/mg protein.
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2.10 Determination of 3-nitrotyrosine (3-NY) in the Renal Tissues
Nitrotyrosine has been considered as footprint of peroxynitrite formation (P.
Pacher, J. S. Beckman, & L. Liaudet, 2007). 3-NY content in the renal tissue
homogenates was determined with the aid of ELISA kit procured from Hycult
Biotech (Frontstraat, Uden, Netherlands). Protocol is depicted below.

Figure 2.2: Protocol for 3-NY determination
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2.11 Determination of Pro-Inflammatory Cytokines in Renal Tissues
Levels of pro-inflammatory cytokines such as TNFα and IL-1β in renal tissue
homogenates were determined using commercially available ELISA kit (R & D
systems, MN, USA). In brief, 50 L of assay diluent was added to the 96-well
microtiter plate, followed by 50 L of serum samples or standards, and incubated for
2 hrs at room temperature (RT). After washing, 100 L of cystatin c conjugate
solution was added and incubated at RT for 2 hours. Subsequent to washing, wells
were probed with 100 L substrate solution and absorbance was determined at 450
nm using microtiter plate reader [Molecular Devices, Sunnyvale, CA, USA]. Values
are expressed as pg / mg protein.
2.12 Determination of MAPK Activation
JNK and p38 MAPK activation in the renal tissues was determined with the
aid of commercially available kit procured from Cell signaling technology (Danvers,
MA, USA). Tissue homogenates 100 L was added to microtiter wells and incubated
for 2hrs at 37C. Contents of the wells were aspirated and washed four times with
wash buffer provided in the kit. Then 100 L of detection antibody was added to the
corresponding wells and incubated for 1hr at 37C. After repeating the washing step,
wells were probed with tetra methylene blue (TMB) substrate solution and
absorbance was measured at 450 nm.
2.13 Determination of Caspase 3 Activity
Caspase 3 activity in the renal tissue homogenate was determined using the kit
purchased from Promega (Madison, WI, USA). Caspase 3 is a protease that
specifically cleaves the aspartate residue of the sequence DEVD (Asp-Glu-Val-Asp).
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In this assay, the 100 L of substrate solution (rhodamine Z-DEVD-R100) is mixed
with 100 L of renal tissue homogenate in a fluorescence microtiter plate and
incubated for 1 hour at RT. Substrate is cleaved by caspase 3 in the samples and this
produces fluorescent rhodamine. Fluorescence is measured by excitation at 499 nm
and emission at 521 nm, using microtiter plate reader at fluorescence reading mode
[Molecular Devices, Sunnyvale, CA, USA].
2.14 Determination of Poly (ADP-ribose) polymerase (PARP) Activity
PARP activities in the renal tissues were determined using the reagents
obtained from Trevigen, Inc. This assay measures the incorporation of biotinylated
poly(ADP-ribose) on to the histone pre-adsorbed in 96-well microtiter strips. In brief,
50 L/well of PARP buffer was added on to microtiter plate to rehydrate histones for
30 min at RT. Contents of the wells were aspirated and 25 L of diluted renal tissue
homogenate and 25 L assay buffer is added and incubated at RT for 60 min. This
was followed by washing and probing of wells with 50 L of diluted streptavidinHRP conjugate and incubated at RT for 60 min. After washing if wells 50 L of
substrate solution was added and incubated in dark for 15 min. The reaction was
arrested by adding 50 L of 0.2M HCl and absorbance was measured at 450 nm.
2.15 Determination of DNA Fragmentation
The assay is based on quantitative sandwich ELISA using mouse monoclonal
antibodies against DNA and histones (Sigma Chemicals). This facilitates the specific
determination of mono and oligonucleosomes in the total tissue homogenates. 20 L
of tissue homogenates were placed on to streptavidin-coated wells. 80 L of antihistone-biotin and anti-DNA-peroxidase was added and incubated at RT for 2 hrs.
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Then unbound components were removed by washing and 100 L of 2,2′-azino-di(3-ethylbenzthiazoline sulfonic acid(ABTS) solution was added and the absorbance
was measured at 405 nm.

Figure 2.3: DNA fragmentation assay principle

2.16 Terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) Staining in Paraffin Embedded Renal Sections
TUNEL staining was performed with the kit obtained from Sigma chemicals.
Cleavage of genomic DNA during apoptosis yields double-stranded, low molecular
weight DNA fragments as well as single strand breaks (nicks) in high molecular
weight DNA. These DNA strand breaks can be identified by labeling free 3’-OH
termini with modified nucleotides in an enzymatic reaction. Paraffin sections were
dewaxed as per the procedure described in section 2.5.1. Then slides were placed in
plastic coplin jar containing 50 ml 0.1 M citrate buffer pH 6.0 (Sigma chemicals) and
microwave irradiated (750 W) for 1 min. Slides were immediately cooled by adding
80 ml of distilled water and then transferred to coplin jar containing PBS. Sections
were then immersed for 30 min in Tris-HCl (0.1 M, pH 7.5) containing 3% bovine
serum albumin (BSA) at RT. After careful washing with PBS, 50 L of TUNEL
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reaction mixture was carefully overlaid on to the sections and incubated at 37C for
60 min in humidified side staining chamber (Electron microscopy sciences, Hatfield,
PA, USA). After washing of slides with PBS, sections were mounted in glycerol
medium and observed under fluorescence microscope using 515-565 nm filter
[Fluorescein isothiocyanate (FITC) filter; EVOS FL, Thermo Fischer Scientific,
Paisley, UK]. Images were acquired at final magnification of X100.
2.17 Statistical Analysis of the Data
Values expressed are mean ± SEM. One-way analysis of variance (ANOVA)
followed by Tukey’s post hoc test was performed. Probability values P < 0.05 were
considered as significant. Analysis was performed with Graph Pad prism V software
(La Jolla, CA, USA).
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Chapter 3 : Results
3.1 GP Treatment Attenuates CP-Induced Renal Tissue Injury
Animals were treated as described in the methods section (2.1) and sacrificed
after 72 hrs. Serum samples were subjected to the determination of clinical markers
for renal tissue injury. Specifically, levels of BUN and creatinine were determined.
As shown in the Figure 3.1, CP treatment resulted in significant renal tissue injury,
which was characterized by elevated levels of BUN (Figure 3.1A) and creatinine
(Figure 3.1B). However, GP elicited dose-dependent nephroprotective actions and
ameliorated CP-induced nephrotoxicity. The maximum nephroprotective activity of
GP was observed at 10 mg/kg. Therefore, in further experiments this concentration
was used in animal experiments.
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Figure 3.1: Effect of GP on CP-induced Renal Tissue Injury (serum creatinine and
BUN). GP at the indicated doses was administered to animals 2 hrs, prior to CP
administration and then sacrificed after 72 hrs. (A) Shows the serum levels of BUN
in the respective group of animals. (B) Shows the serum levels of creatine in the
respective group of animals. n=6/group; # P < 0.001 vs. Veh/Genipin; * P < 0.01 vs.
CP; @ P < 0.001 vs. CP

32
3.2 GP Treatment Attenuates CP-Induced Renal Tissue Injury
We further evaluated the nephroprotective effect of GP against CP-induced
nephrotoxicity by determining the specific biomarkers of acute kidney injury such as
cystatin C and KIM-1 in serum and renal tissue samples. Our observations indicated
that CP induced significant elevations in the levels of cystatin C (Figure 3.2A) and
KIM-1(Figure 3.2B). Upon treatment with GP (10 mg/kg), the levels of cystatin C
and KIM-1 were reduced, indicating the amelioration of CP-induced nephrotoxicity
(Figure 3.2).
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Figure 3.2: Effect of GP on CP-induced Renal Tissue Injury on (Cystatin C and KIM-1). (A) Shows the
serum levels of cystatin-C as determined by ELISA (B) Shows the renal tissue levels of KIM-1 as
determined by ELISA. N=6/group; # P < 0.001 vs. Veh / GP; * P < 0.001 vs. CP
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3.3 Effect of CP and/or GP on Renal Histology
The effects of different treatment modalities on renal histological features
were evaluated by PAS staining as described in the methods section. CP
administration induced severe and widespread tubular necrosis with dilatation,
marked degeneration, intraluminal epithelial anoikis and cast formation. Furthermore,
CP treatment is also characterized by infiltration of immune cells, which are
characteristic of inflammation. However, treatment of animals with GP significantly
improved the histological architecture by attenuating the tubular necrosis and
inflammation (Figure 3.3).
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Figure 3.3: Effect of CP and/or GP on Renal Histology. Shown are the representative
images of PAS stained paraffin embedded kidney sections from the respective group of
animals. Asterisk symbol denotes tubular necrosis with cast formation. Arrowhead
denotes tubular epithelial anoikis and dashed arrow indicated the inflammation foci.
Magnification is X 200
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3.4 Effect of GP on CP-induced Oxidative Stress in Renal Tissues
Oxidative stress is one of the key mechanisms by which CP perpetuates renal
tissue injury (G.-S. Oh et al., 2016). Therefore, we have investigated the various
endogenous markers of oxidative stress and anti-oxidant defense systems in renal
tissues. First, we determined the O2- generating enzyme (NADPH oxidase), which
has been shown to play pivotal role in CP-induced renal damage (Y. Wang et al.,
2015). Our observations revealed that CP significantly induced NADPH oxidase
activity (Figure 3.4A) and this was mitigated upon GP treatment. SOD a major
endogenous defender against oxidant damage was diminished by CP and its activity
was restored by GP (Figure 3.4B). Similar trend was observed with the renal content
of GSH (Figure 3.4C). O2- is powerful oxidant and rapidly reacts with the membrane
lipids, and produces lipid peroxides, which affect the structure and function of the
lipids (Arany & Safirstein, 2003). In fact, our results suggest that levels of 4-HNE
was elevated in the renal tissues of CP treated animals and this was attenuated by GP
(Figure 3.4D).
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Figure 3.4: Effect of GP on CP-induced Oxidative Stress in Renal Tissues. GP attenuates
CP-induced oxidative stress in renal tissues. (A) depicts NADPH oxidase activity; (B)
SOD activity; (C) GSH content and (D) 4-HNE in the respective group. N=6/group; # P
< 0.001 vs. Veh/GP ; * P < 0.01 vs. CP
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3.5 Effect of GP on CP-induced Nitrative stress in Renal Tissues
Reactive nitrogen species (RNS) plays pivotal role in the pathophysiology of
several diseases. ONOO is the formed by coupling of O2- and NO, when they are
simultaneously generated by the phagocytes that invade the renal parenchyma (P.
Pacher, et al., 2007). ONOO being a powerful oxidant rapidly nitrates lipids,
proteins and nucleic acids, due to the lack of endogenous defense system, which
could detoxify them (P. Pacher, et al., 2007). In fact, our results suggest that CP
significantly induced the accumulation of 3-NY in renal tissues and this was
ameliorated upon GP treatment (Figure 3.5).

Figure 3.5: Effect of GP on CP-induced Nitrartive Stress in Renal Tissues. GP
attenuates CP-Induced nitrative stress in renal tissues. Quantification of 3nitrotyrosine levels in the renal tissues. N=6/group; # P < 0.001 vs. Veh/GP; * P <
0.01 vs. CP

39
3.6 Effect of GP on CP-induced Renal Inflammation
Since our earlier histological observation indicated that GP inhibited renal
inflammation, we further confirmed this by quantification of pro-inflammatory
cytokines (TNF-α and IL1β) in the renal tissues by ELISA. As expected, CP
provoked significant increase of these pro-inflammatory cytokines and this was
diminished when the animals were treated with GP (Figure 3.6).

Figure 3.6: Effect of GP on CP-induced Renal Inflammation. GP attenuates CPinduced pro-inflammatory cytokine expression in renal tissues. (A) TNF-α and )B(
IL1-β in the respective group of samples. N=6/group; # P < 0.001 vs. Veh/GP; * P <
0.01 vs. CP

3.7 Effect of GP on CP-induced MAPK Activation
MAPK plays crucial role in cell proliferation, migration, and apoptosis during
growth and development. In addition, they are also implicated in the pathogenesis of
several human diseases. ROS are the potent activators of MAPK and since CP
induces ROS generation, we evaluated the MAPK activation in renal tissues
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(Ganesan Ramesh & W. Brian Reeves, 2005). There was robust activation of p38
MAPK (Figure 3.7A) and JNK (Figure 3.7B) in renal tissues obtained from CP
treated animals, and this was inhibited upon GP treatment (Figure 3.7).

Figure 3.7: Effect of GP on CP-induced MAPK Activation. GP attenuates CPinduced MAPK activation in renal tissues. (A) depicts the p38 MAPK activation and
(B) shows JNK activation in the respective group of animals. n=6/group; # P < 0.001
vs. Veh/GP; * P < 0.001 vs. CP

3.8 Effect of GP on CP-Induced Apoptotic Cell Death
Apoptotic cell death is the major pathway, were renal tissue succumbs to CPtoxicity (Schrier, Wang, Poole, & Mitra, 2004). Therefore, we determined the various
molecular determinants of apoptosis in the kidney tissues (Figure 3.8). There were
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significant increase in the caspase 3 activity (Figure 3.8A) and PARP activation
(Figure 3.8B) in animals that received CP. In addition, DNA fragmentation was
increased in CP treated animals. However, this phenotypic change was mitigated
upon GP treatment.
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Figure 3.8: Effect of GP on CP-induced Apoptotic Cell Death. GP attenuated CPinduced apoptotic cell death in renal tissues. (A) caspase 3 activity, (B) PARP activity
and (C) DNA fragmentation in the respective groups. n=6/group; # P < 0.001 vs.
Veh/GP; * P < 0.001 vs. CP
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3.9 Effect of GP on CP-induced Apoptotic Cell Death – TUNEL staining
We further confirmed the nephroprotective of GP on mitigating CP-induced
apoptotic cell death by TUNEL staining in the paraffin embedded kidney sections. In
fact, there was marked apoptosis characterized by increased TUNEL positive cells in
animals

that

were

administered

CP.

Interestingly,

GP

elicited

marked

nephroprotective action by mitigating the apoptosis, which was evidenced by reduced
number of TUNEL positive cells.

Figure 3.9: Shows the representative TUNEL staining images in the respective group
of animals. White arrowhead indicates the TUNEL positive cells. Magnification is
X100
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3.10 Effect of GP Treatment after the Established Renal Tissue Injury
In this section, we have investigated the therapeutic effect of GP on
mitigating/reversing the established renal tissue injury imparted by CP. To our
surprise, GP significantly attenuated renal tissue injury, which was evidenced by
diminished levels of serum BUN and creatinine levels (Figure 3.10).

Figure 3-10: GP exhibits therapeutic effect against CP-induced renal tissue injury.
(A) Serum BUN levels and (B) serum creatinine levels in respective group of
animals. n=6/group; # P < 0.001 vs. Veh/GP; * P < 0.001 vs. CP.
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3.11 Therapeutic effect of GP on Renal Histology
The therapeutic effect of GP on abrogation of CP-induced nephrotoxicity was
confirmed by PAS staining of respective paraffin embedded kidney sections. In fact,
GP inhibited CP-induced tubular necrosis, degeneration, and renal inflammation
(Figure 3.11).

Figure 3.11: The representative images of PAS stained paraffin embedded kidney
sections from the respective group of animals. Asterisk symbol denotes tubular
necrosis with cast formation. Arrowhead denotes tubular epithelial anoikis and
dashed arrow indicated the inflammation foci. Magnification is X 200
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Chapter 4 : Discussion
Cisplatin (CP) is a potent chemotherapeutic agent that induces AKI by
recruiting oxidative stress, inflammation, and cell death pathways (Yolanda I. Chirino
& Pedraza-Chaverri, 2009). Previous studies have reported that GP elicited antioxidant and anti-inflammatory activity in various pre-clinical studies (S. X. Yu et al.,
2015). In this study, we have investigated the potential nephroprotective actions of
GP against CP-induced nephrotoxicity. Animals administered with CP revealed
marked tubular necrosis, degeneration, and inflammation. Treatment with GP
significantly ameliorated renal tissue injury. Various mediators such as ROS, proinflammatory cytokines and adhesion molecules, can activate leukocytes. In fact, we
have observed reduced renal inflammation, which corroborated with diminished
leukocyte storming to the site of tissue injury (Faubel et al., 2007) (Donnahoo et al.,
1999).
GSH is the pivotal endogenous antioxidant molecule that maintains the redox
homeostasis in the cells and tissues (Atessahin, Yilmaz, Karahan, Ceribasi, &
Karaoglu, 2005). GSH protects the biomolecules from oxidative tissue damage by
scavenging ROS (Atessahin, et al., 2005). Previous studies had reported depletion of
GSH by CP via forming direct adducts (Yilmaz et al., 2004). Decreased GSH levels
in the renal tissues further perpetuates CP-induced renal damage. Herein, we have
observed that CP-induced GSH depletion was inhibited by GP treatment. In fact, our
findings are consistent with previous reports that GP could restore the cellular thiol
pool. Diminished endogenous antioxidant reserve capacity is often observed in
patients receiving cancer chemotherapy. In particular, this scenario is more
pronounced in subjects on CP regimen.
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ROS can be generated by endogenous or exogenous sources. In particular,
NADPH oxidase has been implicated as key source for CP induced O2 in the renal
tissues (Y. Wang, et al., 2015). It is pertinent to note that NADPH oxidase (phagocyte
oxidase) is highly expressed in leukocytes, particularly in macrophages and
neutrophils (Y. Wang, et al., 2015). In our present study, we have observed that GP
inhibited NADPH oxidase activation by CP, probably via mitigation of leukocyte
activation. Levels of 4HNE depict the ROS mediated lipid peroxidation. Previous
study has shown that SOD plays pivotal role in limiting ROS-induced tissue damage
(B. P. Yu, 1994). GSH participates in regeneration of cellular lipid molecules via
reacylation of cell membrane components (B. P. Yu, 1994). Therefore, to investigate
the antioxidant effects of GP against CP-induced renal tissue damage, we have
determined GSH levels, SOD activity, and 4HNE content. In fact, we observed that
GP significantly inhibited oxidative stress by restoring GSH levels, SOD activity and
diminishing 4HNE accumulation.
ONOO is an important mediator implicated in the reactive nitrogen species
mediated tissue injury. ONOO generation is accelerated in cells and tissues, due to
the lack of endogenous defense system available to detoxify this noxious and highly
reactive oxidant molecule (Speckmann, Steinbrenner, Grune, & Klotz, 2016)
(Trujillo, Ferrer-Sueta, & Radi, 2008). The other factor contributing to enhanced
generation of ONOO , could occur in scenario wherein, NO and O2 are
simultaneously generated by activated leukocytes (Pál Pacher, et al., 2007).
Therefore, it is pertinent to note that genetic ablation of inducible nitric oxide
synthase (iNOS) or treatment with chemical ONOO decomposition catalysts
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prevented CP-induced renal tissue damage (Y. I. Chirino, Hernandez-Pando, &
Pedraza-Chaverri, 2004) (Y. I. Chirino et al., 2008). Our findings are also in
agreement with these observations, since GP inhibited accumulation of 3NY in CP
treated animals.
Previous studies have indicated that production of pro-inflammatory cytokines
is mediated by NFκB activation (Barry, Behnke, & Eastman, 1990). In this study, we
have observed that GP attenuated pro-inflammatory cytokine expression in the renal
tissues. However, the exact role of NFκB in this context needs to be explored further.
ROS has been reported to be the key mediator involved the activation of MAPK
(Persons, Yazlovitskaya, Cui, & Pelling, 1999) (G. Ramesh & W. B. Reeves, 2005).
CP has been shown to stimulate the hydroxyl radical generation (H. Liu & Baliga,
2003). Production of hydroxyl radical by CP in renal tissues, is demonstrated due to
the release of iron from the heme group of cytochrome P 450 2E1 (H. Liu & Baliga,
2003). Furthermore, previous studies have reported that genetic ablation of TNF-α
resulted in decreased ROS generation, MAPK activation and cell death pathways
activated by CP in renal tissues (Zhang, Ramesh, Norbury, & Reeves, 2007). In fact,
our findings accede with these observations, because GP attenuated leukocyte
activation, ROS generation and MAPK activation.
CP targets neoplastic and naïve cells resulting in DNA damage. To counteract
the DNA damage, DNA repair enzymes are pressed in to service. PARP is a
ubiquitous nuclear enzyme that actively participates in DNA repair mechanism (Bai,
Nagy, Fodor, Liaudet, & Pacher, 2015). However during the enhanced tissue injury,
hyper activation of PARP results in depletion of cellular ATP levels, that activates
extrinsic pathway of apoptosis (Pacher & Szabo, 2008). Interestingly, either
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pharmacological inhibition of PARP or genetic ablation, protected the mice from CPinduced renal tissue damage (P. Mukhopadhyay et al., 2011). In our present study, we
have also observed that GP inhibited extrinsic pathway of cell death via inhibition of
PARP, caspase3 activation and DNA fragmentation. In summary, findings emanating
from the present study indicated that inhibition of oxidative stress, inflammation, and
apoptosis pathways by GP could represent as novel strategy to counteract CP-induced
AKI.
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Chapter 5 : Conclusions and Future Directions
1. To our knowledge, this is the first study to report the nephroprotective
activity of GP against CP-induced renal tissue injury. Specifically GP
attenuated CP-induced renal toxicity via mitigation of oxidative stress,
inflammation, and cell death pathways.
2. GP exhibited both prophylactic and therapeutic nephroprotective
effects against CP-induced renal tissue damage.
3. Further studies are warranted to completely understand the molecular
mechanisms governing GP nephroprotective activity.
4. To establish the GP renoprotective actions, further studies are
warranted, in rodents harboring tumors that are sensitive to CSP. This
is to ascertain that GP beneficial effects do not compromise/interfere
with the CP anti-tumor activity.
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